tradingkey.logo
tradingkey.logo

Guardant Health’S Infinityai Real-World Evidence Supports Approval Of Enhertu® For Previously Treated Patients With Her2-Positive Metastatic Solid Tumors In Japan

ReutersMar 30, 2026 2:11 PM

- Guardant Health Inc GH.O:

  • GUARDANT HEALTH’S INFINITYAI REAL-WORLD EVIDENCE SUPPORTS APPROVAL OF ENHERTU® FOR PREVIOUSLY TREATED PATIENTS WITH HER2-POSITIVE METASTATIC SOLID TUMORS IN JAPAN

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI